KSH-01

N/A

Report date: 2024/02/01 13:25:23

Base Information

Drug NameKSH-01
Drug Alias NameAutologous CD4+/CD8+ T cells transduced with lentiviral vector directed against MAGE-A4 antigen (TCRx Therapeutics)KSH-01KSH01-TCRTKSH01-A4-TCR-T
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > TCR therapy
Mechanisms of ActionT lymphocyte replacementsAnti-Melanoma-associated antigen 4
TargetsMelanoma-associated antigen 4
Therapy Area/IndicationsSolid tumours
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesTCRx Therapeutics Co Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesTCRx Therapeutics Co Ltd
Inactive CompaniesN/A
Active IndicationsSolid tumours
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A